UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A
October 13, 2016 16:01 ET
|
BioMarin Pharmaceutical Inc.
Phase 1/2 Study Expected to Resume by End of 2016 Requirement for Prophylactic Corticosteroids Removed SAN RAFAEL, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc....
BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET
October 11, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics
September 21, 2016 08:53 ET
|
BioMarin Pharmaceutical Inc.
BioMarin to Seek Review of Ruling in Composition of Matter Patent Interference (No. 106,008) Patent Trial and Appeal Board Ruled in BioMarin’s Favor on Method of Use (MOU) Patent Interference (No....
BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease
September 15, 2016 08:37 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization...
BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease
September 06, 2016 16:05 ET
|
BioMarin Pharmaceutical Inc.
Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017 Additional 8 Months of Treatment (81-Week Data) Show Maintenance of Efficacy, Consistent with...
BioMarin to Attend Upcoming Investor Conferences
August 31, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
Citi’s 11th Annual Biotech Conference September 7 in Boston Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York Leerink Partners...
Forbes Ranks BioMarin 10th Most Innovative Company in the World
August 24, 2016 09:53 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most...
BioMarin Announces Pricing of Public Offering of Common Stock
August 09, 2016 09:00 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common...
BioMarin Announces Public Offering of Common Stock
August 08, 2016 16:32 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its...
BioMarin Announces Second Quarter 2016 Financial Results
August 04, 2016 16:03 ET
|
BioMarin Pharmaceutical Inc.
- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million- Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; Vimizim...